ArticleJournal of pediatric gastroenterology and nutrition2026
Beyond eosinophils: A proteomic dissection of remodeling and inflammation in suspected eosinophilic esophagitis.
Article in Journal of pediatric gastroenterology and nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Immune Architecture of Eosinophilic Esophagitis: Mechanisms, Therapeutic Targets, and Precision Management.ImmunoTargets and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectivesEosinophilic esophagitis (EoE) is characterized by eosinophilic inflammation and epithelial remodeling. However, current biomarkers focus predominantly on eosinophilia, overlooking basal cell hyperplasia (BCH), a histologic feature that may persist despite treatment. We aimed to differentiate EoE from non-EoE based on inflammatory biomarker profiles, identify biomarkers associated with BCH, and explore their relation toPPI response and food impaction using high-throughput proteomics.
methodsWe conducted a prospective case-control study of patients aged 6-65 undergoing upper endoscopy for suspected EoE. Histology classified patients as EoE (>15 eos/hpf), non-EoE, and assessed for the presence of BCH. Serum was analyzed using the Olink® Explore 384 Inflammation Panel. We compared biomarker expression between EoE versus non-EoE, and BCH versus non-BCH, with adjustment for age, sex, and atopic disease. Exploratory analyses investigated biomarkers related to PPI response and food impaction.
resultsAmong 86 patients, 26 (30.2%) had EoE and 32 (37.2%) had BCH. CCL26, a marker of eosinophilic inflammation, was the most significantly upregulated biomarker in EoE, was also elevated in BCH, and remained nominally significant even after adjusting for maximum eosinophil count. ITGA11 and TNFRSF11A were nominally associated with BCH independent of eosinophil count. COL9A1 was nominally associated with PPI response and downregulated in non-EoE patients. Oncostatin M (OSM) and TGF-α were nominally associated with food impaction.
conclusionsHigh-throughput proteomic profiling revealed distinct biomarker signatures in EoE. CCL26 was the most significantly upregulated marker, associated with both eosinophilic inflammation and epithelial remodeling. COL9A1 may be associated with GERD-related inflammation and PPI responsiveness. These findings support a dual-pathway model of EoE and suggest potential for biomarker-guided diagnosis and treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.